Not Yet RecruitingNot Applicable

The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry

350 participantsStarted 2026-07-31

Plain-language summary

The STRIDE Registry will evaluate the real-world effectiveness and safety of dupilumab in participants with COPD. The primary objective is to describe characteristics of participants newly initiated with dupilumab for COPD. Secondary objectives are to determine whether treatment with dupilumab reduces moderate and/or severe COPD exacerbations; to determine the impact of treatment on lung function in COPD participants; to determine whether treatment with dupilumab improves the quality of life in COPD participants; and to describe safety of dupilumab among COPD participants. The external control cohort will include participants with COPD from the National Patient-Centered Clinical Research Network (PCORnet) consortium who are not being treated with dupilumab. In addition, chest images will be collected and banked for future research projects and consented participants will perform home spirometry.

Who can participate

Age range

40 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * COPD patients who are newly referred to start dupilumab treatment * Age ≥ 40 years * Standard of care spirometry performed concurrently with the baseline visit or within 90 days prior to the baseline visit Exclusion Criteria: * Patients who have contraindication to dupilumab according to the United States Prescribing Information (USPI) * Any condition that, in the opinion of the Investigator, may interfere with the patient's ability to participate in the study, such as short life expectancy, or other comorbidities that can predictably prevent the patient from completing the schedule of assessments * Patients currently participating in any interventional clinical trial The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Participant Characteristics

Timeframe: End of study (24 months after the last participant is enrolled)

Participant Characteristics

Timeframe: End of study (24 months after the last participant is enrolled)

Patient Characteristics

Timeframe: End of study (24 months after the last participant is enrolled)

Participant Characteristics

Timeframe: End of study (24 months after the last participant is enrolled)

Patients Characteristics

Timeframe: End of study (24 months after the last participant is enrolled)

Patients Characteristics

Timeframe: End of study (24 months after the last participant is enrolled)

Patient Characteristics

Timeframe: End of study (24 months after the last participant is enrolled)

Trial details

NCT IDNCT07612878

SponsorSanofi

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2029-06-30

Contact for this trial

Trial Transparency Trial Transparency

800-633-1610 option 6 Contact-us@sanofi.com

View on ClinicalTrials.gov More COPD (Chronic Obstructive Pulmonary Disease) trials

Plain-language summary

Who can participate

Age range

40 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Participant Characteristics

Timeframe: End of study (24 months after the last participant is enrolled)

Participant Characteristics

Timeframe: End of study (24 months after the last participant is enrolled)

Patient Characteristics

Timeframe: End of study (24 months after the last participant is enrolled)

Participant Characteristics

Timeframe: End of study (24 months after the last participant is enrolled)

Patients Characteristics

Timeframe: End of study (24 months after the last participant is enrolled)

Patients Characteristics

Timeframe: End of study (24 months after the last participant is enrolled)

Patient Characteristics

Timeframe: End of study (24 months after the last participant is enrolled)